S580
Clinical – Head & neck
ESTRO 2026
Guihard S, Chapet S, Thureau S, Auberdiac P, Pommier P, Ruffier A, Perrier L, Devillers A, Campillo-Gimenez B, de Crevoisier R. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023 Aug 1;9(8):1056-1064 Keywords: MRI-guidance, adaptive radiotherapy, xerostomia Long term outcomes of metastasis directed therapy for patients with oligometastatic nasopharyngeal carcinoma Cheuk Lam Sharon Ho, Justin Kar Wai Ng, Chun Yin Edwin Wong Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong Purpose/Objective: Limited data exists on the outcomes of metastasis directed therapy (MDT) for oligometastatic nasopharyngeal carcinoma. We conducted a single- institution retrospective analysis on the long-term outcomes of patients with oligometastatic nasopharyngeal cancer treated with stereotactic body radiotherapy (SBRT), high dose palliative radiotherapy or surgical metastatectomy. Material/Methods: We retrospectively reviewed electronic medical records of patients with oligometastatic Digital Poster 1775 nasopharyngeal carcinoma (5 or less distant metastatic sites) treated at our institution who received either SBRT, high dose palliative radiotherapy (EQD2 >/= 50Gy) or surgical metastatectomy to all known oligometastatic sites. Patterns of oligometastatic disease were stratified by de novo oligometastatic disease (OMD), metachronous oligorecurrence or metachronous oligoprogression. Patients with de novo OMD received 4-6 cycles of palliative platinum-based chemotherapy and radical dose radiotherapy (up to 70Gy) to the nasopharynx and neck, with imaging-proven stable disease control before the delivery of MDT. Local and distant failure rates were analysed, with local failure defined as recurrence or progression in the previously treated oligometastatic sites. Progression free survival (PFS) and overall survival (OS) were evaluated with Kaplan- Meier method. Results: A total of 28 patients were included for analysis. Median follow up was 132 months. The majority (27/28) had 3 or less metastatic sites. 18 patients received SBRT, 8 had high dose palliative RT and 2 underwent surgical metastectomy. SBRT dose
Conclusion: DailyMRI-guided radiotherapy combined with weekly MRI-guided adaptive radiotherapy significantly reduced grade 2+ xerostomia compared to historical results using standard IMRT, without compromising local efficacy. References: 1. Nutting CM, Morden JP, Harrington KJ, et al: Parotid- sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12:127-36, 20112. Castelli J, Thariat J, Benezery K, Hasbini A, Gery B, Berger A, Liem X,
Made with FlippingBook - Share PDF online